FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
44 letters match. Newest first.
-
DrugsLGM Pharma Solutions, LLC
FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.
High risk -
DrugsUSV Private Limited
FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.
High risk -
DrugsConroe Welding Supply, Inc.
FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).
High risk -
DevicesNext Medical Products Company, LLC
FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.
High risk -
DrugsRohto Pharmaceutical Co., Ltd.
FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.
High risk -
DrugsBaxter International Inc.
Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.
High risk -
DevicesO.N. Diagnostics, LLC
FDA says O.N. Diagnostics sold changed VirtuOst VFA software without required clearance and had quality and reporting failures.
High risk -
DrugsFresenius Kabi USA LLC
FDA warns Fresenius Kabi USA over manufacturing failures for sterile injectables at Melrose Park, including endotoxin contamination and media fill failures.
High risk -
DrugsBentley Laboratories LLC
Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.
High risk -
DrugsFresenius Medical Care AG & Co. KGaA
Fresenius Medical Care's Ogden, Utah plant failed to investigate leaking peritoneal dialysis bags, leading to a 2026 recall.
High risk -
DrugsReliance Life Sciences Private Limited
FDA warned India's Reliance Life Sciences over falsified microbiology records and aseptic failures in sterile drug production, prompting a recall.
High risk -
DrugsShoolin Pharma Chem LLP
Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.
High risk -
DrugsAuriga Research Pvt. Ltd.
Auriga Research, an Indian contract drug testing lab, failed to keep complete lab records and properly investigate failing test results.
High risk -
DevicesNipro Renal Solutions USA, Corporation
Nipro Renal Solutions USA released hemodialysis dialysate lots with out-of-spec endotoxin (bacterial toxin) and had widespread quality-system failures, FDA says.
High risk -
DrugsABS Corporation
ABS Corporation released out-of-specification veterinary drugs and used inadequately tested raw materials, FDA says.
High risk -
DevicesLinemaster Switch Corporation
Linemaster Switch Corporation, a Connecticut maker of foot pedals for medical lasers, was cited for quality system failures after an FDA inspection.
High risk -
DrugsFareva Amboise
FDA warned Fareva Amboise in France about sterile drug manufacturing failures, including aseptic practice and data integrity problems.
High risk -
DevicesZIIP, Inc.
FDA warns ZIIP over quality-system violations and unapproved marketing of HALO 2.0, DOT, and gels.
High risk -
DrugsExcelvision - Fareva
FDA warned Excelvision-Fareva after a 2026 inspection found inadequate contamination investigations and aseptic failures for sterile drugs.
High risk -
DrugsWizcure Pharmaa Private Limited
FDA warned Wizcure Pharmaa about serious manufacturing and data-integrity failures in sterile OTC drugs.
High risk -
Devices3B Medical, Inc. dba Reach Health, Inc.
FDA warns Reach Health over unapproved APAP use change and complaint/CAPA failures.
High risk -
DrugsPharmathen International S.A.
FDA warns Pharmathen over inadequate aseptic controls at its Greek plant making sterile drugs for the U.S.
High risk -
DevicesZOLL Medical Corporation
FDA warned ZOLL Medical after an inspection found quality-system, design-validation, supplier, and reporting failures for defibrillators, ventilators, and electrodes.
High risk -
DrugsLaboratorios Jaloma S.A. de C.V.
FDA found Laboratorios Jaloma’s OTC drug lab records were inaccurate, microbial tests unvalidated, and electronic data missing or uncontrolled.
High risk -
DrugsHarbin Jixianglong Biotech Co., Ltd.
FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.
High risk -
DrugsCareFusion 213, LLC
FDA warns CareFusion 213 over inadequate investigations and contamination controls at its El Paso sterile drug plant.
High risk -
DrugsAva Inc.
FDA warned Ava Inc. about adulterated drugs after an inspection found data-integrity failures and hidden trial injections in its Willowbrook, Illinois lab.
High risk -
DrugsIntas Pharmaceuticals Limited
FDA warns Intas Pharmaceuticals' Dehradun, India plant over weak out-of-spec investigations and untracked batch-record edits for its tablets.
High risk -
DevicesMedline Industries, LP
Medline's Glen Falls, NY plant made angiographic syringes and kits under flawed CAPA, cleaning and design verification controls, FDA says.
High risk -
DrugsMicrobiological Testing & Consulting, LLC
FDA warned contract testing lab Microbiological Testing & Consulting over CGMP violations in drug product microbiological testing.
High risk -
DevicesLonghorn Vaccines and Diagnostics LLC
Longhorn Vaccines and Diagnostics sold its PrimeStore MTM sample transport device without required quality controls or clearance for claims beyond its approved uses.
High risk -
DevicesIsoTis OrthoBiologics, Inc.
IsoTis OrthoBiologics in Irvine, CA failed to properly fix and assess possible particulate contamination in its Accell bone filler devices, FDA says.
High risk -
DevicesAvertix Medical, Inc.
FDA warns Avertix Medical over Guardian implantable cardiac event detector quality violations and late injury reports.
High risk -
DrugsSimtra BioPharma Solutions
FDA found contamination risks in Simtra's sterile drug manufacturing in Germany, including microbial recoveries, failed isolator tests, and inadequate decontamination.
High risk -
DevicesExactech, Inc. dba Advita Ortho
FDA warned Exactech/Advita Ortho over quality-system failures in Equinoxe shoulder implants found during a July 2025 Sarasota inspection.
High risk -
FoodBlack Sheep Egg Company, LLC
Black Sheep Egg Company in Walnut Ridge, Arkansas, found Salmonella throughout its shell egg plant and insanitary conditions.
High risk -
DevicesBeta Bionics, Inc.
FDA says Beta Bionics' iLet Bionic Pancreas system had quality-system failures, including ignored complaints of severe hypoglycemia and diabetic ketoacidosis.
High risk -
DrugsCohance Lifesciences Limited
Cohance Lifesciences, a finished-drug maker, was cited for inadequate investigations and dirty shared equipment that caused cross-contamination.
High risk -
DevicesFlextronics America LLC
FDA warns Flextronics America, contract maker of FreeStyle Libre 3 glucose sensors in Austin, TX, over an unvalidated assembly step and weak corrective actions.
High risk -
DevicesUnomedical Device S.A. de C.V.
FDA warns Unomedical over insulin infusion sets with unvalidated leak tests and unreported serious injuries.
High risk -
DevicesMeridian Bioscience, Inc
FDA warns Meridian Bioscience's Magellan Diagnostics over quality system failures and unreported problems with its blood lead test kits.
High risk -
DrugsWinder Laboratories, LLC
FDA warns Winder Laboratories of adulterated prescription drugs due to cleaning and facility failures.
High risk -
DrugsTower Laboratories Ltd.
FDA warned Tower Laboratories, an OTC drug maker in Montague, MI, for weak out-of-specification investigations and unproven test methods.
High risk -
DrugsUnipack LLC
FDA says Unipack LLC released suppositories without adequate out-of-specification investigations, complete lab records, and required USP testing.
High risk